"Cardiotonic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
| Descriptor ID |
D002316
|
| MeSH Number(s) |
D27.505.954.411.222 D27.720.799.080
|
| Concept/Terms |
Cardiotonic Agents- Cardiotonic Agents
- Cardiac Stimulants
- Inotropic Agents, Positive Cardiac
- Cardiotonic Drugs
- Cardiotonics
- Myocardial Stimulants
- Cardioprotective Agents
|
Below are MeSH descriptors whose meaning is more general than "Cardiotonic Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiotonic Agents".
This graph shows the total number of publications written about "Cardiotonic Agents" by people in this website by year, and whether "Cardiotonic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 2 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 2 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 3 | 3 |
| 2005 | 1 | 3 | 4 |
| 2006 | 7 | 0 | 7 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 2 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 3 | 6 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 2 | 3 |
| 2014 | 5 | 4 | 9 |
| 2015 | 2 | 4 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 1 | 4 |
| 2019 | 5 | 2 | 7 |
| 2020 | 2 | 2 | 4 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 1 | 3 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiotonic Agents" by people in Profiles.
-
Pulmonary artery pulsatility index predicts prolonged inotrope/pulmonary vasodilator use after implantation of continuous flow left ventricular assist device. Congenit Heart Dis. 2019 Nov; 14(6):1130-1137.
-
Another Outcome Lost to the Benefits of Levosimendan? Pediatr Crit Care Med. 2019 10; 20(10):992-994.
-
Congestive Heart Failure in Children. Pediatr Rev. 2019 Feb; 40(2):60-70.
-
TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice. Cardiovasc Ther. 2018 Oct; 36(5):e12462.
-
Strain and Strain Rate Measured on Echocardiogram 1-3?Weeks after Starting Treatment Is Worse in Acute Dilated Cardiomyopathy Pediatric Patients with Poor Outcomes at One Year. Echocardiography. 2015 Nov; 32(11):1688-96.
-
Vasopressin versus dopamine for treatment of hypotension in extremely low birth weight infants: a randomized, blinded pilot study. J Pediatr. 2015 Apr; 166(4):850-5.
-
Critical care of patients with paediatric valvar cardiac disease. Cardiol Young. 2014 Dec; 24(6):1071-6.
-
National prescribing trends for heart failure medications in children. Congenit Heart Dis. 2015 Jan-Feb; 10(1):78-85.
-
Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging. 2014 Mar; 15(3):324-31.
-
Possible digoxin toxicity associated with concomitant ciprofloxacin therapy. Int J Clin Pharm. 2013 Oct; 35(5):673-6.